CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to ESALY

Lenvatinib

Phase 3
Eisai (ESALY)

Phase 3

Development Phase

5

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q3 '27
ESALYPhase 2

Lenvatinib Phase 2 Est. Readout

Lenvatinib
Q3 2027~QSTALE
CT.gov
00%
Q2 '27
ESALYPhase 3

Lenvatinib Phase 3 Est. Readout

Lenvatinib
Q2 2027~Q
CT.gov
00%
Apr '27
ESALYPhase 2

Lenvatinib Phase 2 Est. Readout

Lenvatinib
Apr 2027~
CT.gov
00%
Dec '26
ESALYPhase 2

Lenvatinib Phase 2 Est. Readout

Lenvatinib
Dec 2026~
CT.gov
00%
Nov '26
ESALYPhase 2

Lenvatinib Phase 2 Est. Readout

Lenvatinib
Nov 2026~
CT.gov
00%
Competitive Landscape

2 competitors in Hepatocellular Carcinoma

View Full Landscape
Drug Information

Target Indication

Hepatocellular Carcinoma

Clinical Trial

NCT00946153

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.